Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
February 9, 2007

Q-Med and Medy-Tox Join Forces to Develop Botulinum Toxin Products

  • Q-Med and Medy-Tox entered into an collaboration agreement for botulinum toxin-based biopharmaceuticals. Q-Med will develop and commercialize new generations of these products for both esthetic and therapeutic indications.

    Under the agreement, Q-Med will pay Medy-Tox milestones up to $8 million provided that specific targets are met. Medy-Tox is entitled to royalties on products developed by Q-Med that are based on its active pharmaceutical ingredients.

    Medy-Tox retains the right of first refusal regarding distribution in India, Thailand, Singapore, and South Korea of newly developed botulinum toxin products.

    In return for Medy-Tox’ support, Q-Med will provide an additional conditioned $3 million to help Medy-Tox expand its facilities in Ochang-myeon in South Korea.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.